UY36305A - Compuestos de esteroides c-20, sus composiciones y usos para tratar lesión cerebral traumática (tbi), que incluyen conmociones cerebrales. - Google Patents

Compuestos de esteroides c-20, sus composiciones y usos para tratar lesión cerebral traumática (tbi), que incluyen conmociones cerebrales.

Info

Publication number
UY36305A
UY36305A UY0001036305A UY36305A UY36305A UY 36305 A UY36305 A UY 36305A UY 0001036305 A UY0001036305 A UY 0001036305A UY 36305 A UY36305 A UY 36305A UY 36305 A UY36305 A UY 36305A
Authority
UY
Uruguay
Prior art keywords
tbi
compositions
conmotions
steroid compounds
brain injury
Prior art date
Application number
UY0001036305A
Other languages
English (en)
Inventor
Daniel Emil Levy
Original Assignee
Prevacus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prevacus Inc filed Critical Prevacus Inc
Publication of UY36305A publication Critical patent/UY36305A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0062—Estrane derivatives substituted in position 17 alfa not substituted in position 17 beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J15/00—Stereochemically pure steroids containing carbon, hydrogen, halogen or oxygen having a partially or totally inverted skeleton, e.g. retrosteroids, L-isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/006—Ketals at position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0007—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa
    • C07J5/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
    • C07J7/0045—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa not substituted in position 16

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a compuestos de esteroides C-20, sus composiciones y métodos de uso para tratar, minimizar y/o evitar una lesión cerebral traumática (TBI), que incluyen TBI grave, TBI moderada y TBI leve, que incluyen las conmociones cerebrales.
UY0001036305A 2014-09-17 2015-09-17 Compuestos de esteroides c-20, sus composiciones y usos para tratar lesión cerebral traumática (tbi), que incluyen conmociones cerebrales. UY36305A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462051898P 2014-09-17 2014-09-17
US201462052457P 2014-09-18 2014-09-18

Publications (1)

Publication Number Publication Date
UY36305A true UY36305A (es) 2016-04-29

Family

ID=55533838

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036305A UY36305A (es) 2014-09-17 2015-09-17 Compuestos de esteroides c-20, sus composiciones y usos para tratar lesión cerebral traumática (tbi), que incluyen conmociones cerebrales.

Country Status (18)

Country Link
US (1) US20160168190A1 (es)
EP (1) EP3194417B1 (es)
JP (1) JP2017527603A (es)
KR (1) KR20170103745A (es)
CN (1) CN107108689A (es)
AU (1) AU2015317652A1 (es)
BR (1) BR112017005168A2 (es)
CA (1) CA2961630A1 (es)
CL (1) CL2017000644A1 (es)
EA (1) EA201790430A1 (es)
ES (1) ES2855993T3 (es)
IL (1) IL251239A0 (es)
PH (1) PH12017500500A1 (es)
SG (1) SG11201702118YA (es)
TW (1) TW201625660A (es)
UY (1) UY36305A (es)
WO (1) WO2016044559A1 (es)
ZA (1) ZA201701975B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023069126A1 (en) 2021-10-19 2023-04-27 Odyssey Health, Inc. Breath-powered nasal devices for treatment of traumatic brain injury (tbi), including concussion, and methods and methods

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3248390A (en) * 1963-10-10 1966-04-26 Syntex Corp 19-nor-10alpha-pregnene and delta1(10)-19-nor-5alpha-pregnene compounds
FR2097045A1 (en) * 1970-07-30 1972-03-03 Roussel Uclaf 17-ethynylgon-4-en-3-ones - with progestomimetic activity useful as contraceptives and for gynaecological disorders
US5792757A (en) * 1994-08-04 1998-08-11 Pherin Pharmaceuticals 19-nor-pregnane steroids as neurochemical initiators of change in human hypothalamic function
WO2009108804A2 (en) * 2008-02-26 2009-09-03 Emory University Steroid analogues for neuroprotection
CN108976272B (zh) * 2011-10-14 2021-05-25 萨奇治疗股份有限公司 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途
CN103073612B (zh) * 2013-02-04 2015-11-04 山东大学 醋酸乌利司他关键中间体的制备方法
UY36741A (es) * 2015-06-21 2016-12-30 Prevacus Inc Compuesto de esteroide c-20, sus composiciones y usos para tratar la lesión cerebral traumática (tbi), que incluye las conmociones cerebrales

Also Published As

Publication number Publication date
PH12017500500A1 (en) 2017-08-30
BR112017005168A2 (pt) 2018-01-23
SG11201702118YA (en) 2017-04-27
TW201625660A (zh) 2016-07-16
EP3194417A1 (en) 2017-07-26
KR20170103745A (ko) 2017-09-13
CA2961630A1 (en) 2016-03-24
EP3194417B1 (en) 2020-10-28
ES2855993T3 (es) 2021-09-27
WO2016044559A1 (en) 2016-03-24
US20160168190A1 (en) 2016-06-16
EP3194417A4 (en) 2018-12-19
EA201790430A1 (ru) 2017-08-31
ZA201701975B (en) 2019-06-26
IL251239A0 (en) 2017-05-29
CL2017000644A1 (es) 2018-04-02
AU2015317652A1 (en) 2017-04-06
CN107108689A (zh) 2017-08-29
JP2017527603A (ja) 2017-09-21

Similar Documents

Publication Publication Date Title
UY36741A (es) Compuesto de esteroide c-20, sus composiciones y usos para tratar la lesión cerebral traumática (tbi), que incluye las conmociones cerebrales
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
GT201600233A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
UY37134A (es) Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4
SV2018005709A (es) 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa
MX2017013562A (es) Reguladores de microbioma y usos relacionados de los mismos.
CL2017001046A1 (es) Inhibidoes del bromodominio
CL2018002505A1 (es) Inhibidores del envejecimiento proteico-proteico wdr5
UY36530A (es) Métodos para purificar cannabinoides, composiciones y kits de estos
PH12019500494A1 (en) Formulations of (r)-2-amino-3-phenylpropyl carbamate
DOP2016000194A (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
CL2019000304A1 (es) Fracciones de plasma en sangre como tratamiento para tratamientos cognitivos relacionados con el envejecimiento.
BR112017002332A2 (pt) terapia de combinação para o tratamento de um paramixovírus
ECSP19015192A (es) Composiciones y métodos de inhibir masp-3 para el tratamiento de diversas enfermedades y trastornos
BR112016023558A2 (pt) compostos úteis como imunomoduladores
UY37018A (es) Inhibidores bicíclicos de pad4
CL2017002719A1 (es) Imidazopirazinonas como inhibidores de pde1
UY37017A (es) Inhibidores aza-bencimidazol de pad4
CL2018002810A1 (es) Anticuerpos anti-factor bb del complemento y usos de estos referencia cruzada.
CL2019002251A1 (es) Anticuerpos contra triptasa, composiciones de estos y usos de estos.
MX2019013808A (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer.
GT201600250A (es) Compuestos de 1, 3, 4- tiadiazol y uso de los mismos para el tratamiento del cáncer
CL2016002463A1 (es) Composiciones farmacéuticas sólidas que comprenden derivados de biopterina y usos de tales composiciones.
BR112017012581A2 (pt) tratamento de degeneração da retina com o uso de células progenitoras
CL2017000827A1 (es) Inhibidores de aldosterona sintasa

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20230508